161P - Tumor mutational burden assessed by a targeted NGS assay predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer
| Autor: | Jermann, P., Alborelli, I., Leonards, K., Rothschild, S.I., Leuenberger, L., Savic Prince, S., Mertz, K., Poechtrager, S., Zippelius, A., Quagliata, L., Bubendorf, L. |
|---|---|
| Zdroj: | In Annals of Oncology April 2019 30 Supplement 2:ii59-ii59 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|